Clinical trial NCT00000526 - References

Cardiovascular Diseases — Cardiac Arrhythmia Suppression Trial (CAST)

Citation(s)

•   A symposium: the cardiac arrhythmia suppression trial--does it alter our concepts of and approaches to ventricular arrhythmias? Woodland, Texas, August 9, 1989
  Am J Cardiol. 1990 Jan 16;65(4):1B-42B.
•   Akiyama T, Pawitan Y, Campbell WB, Papa L, Barker AH, Rubbert P, Friedman L, Keller M, Josephson RA
  Effects of advancing age on the efficacy and side effects of antiarrhythmic drugs in post-myocardial infarction patients with ventricular arrhythmias. The CAST Investigators. J Am Geriatr Soc. 1992 Jul;40(7):666-72.
•   Akiyama T, Pawitan Y, Greenberg H, Kuo CS, Reynolds-Haertle RA
  Increased risk of death and cardiac arrest from encainide and flecainide in patients after non-Q-wave acute myocardial infarction in the Cardiac Arrhythmia Suppression Trial. CAST Investigators. Am J Cardiol. 1991 Dec 15;68(17):1551-5.
•   Anderson JL, Karagounis LA, Stein KM, Moreno FL, Ledingham R, Hallstrom A
  Predictive value for future arrhythmic events of fractal dimension, a measure of time clustering of ventricular premature complexes, after myocardial infarction. CAST Investigators. Cardia Arrhythmia Suppression Trial. J Am Coll Cardiol. 1997 Jul;30(1):226-32.
•   Anderson JL, Platia EV, Hallstrom A, Henthorn RW, Buckingham TA, Carlson MD, Carson PE
  Interaction of baseline characteristics with the hazard of encainide, flecainide, and moricizine therapy in patients with myocardial infarction. A possible explanation for increased mortality in the Cardiac Arrhythmia Suppression Trial (CAST). Circulation. 1994 Dec;90(6):2843-52.
•   Bigger JT Jr
  Implications of the Cardiac Arrhythmia Suppression Trial for antiarrhythmic drug treatment. Am J Cardiol. 1990 Feb 20;65(8):3D-10D; discussion 68D-71D.
•   Bigger JT Jr
  The events surrounding the removal of encainide and flecainide from the Cardiac Arrhythmia Suppression Trial (CAST) and why CAST is continuing with moricizine. J Am Coll Cardiol. 1990 Jan;15(1):243-5.
•   Brooks MM, Gorkin L, Schron EB, Wiklund I, Campion J, Ledingham RB
  Moricizine and quality of life in the Cardiac Arrhythmia Suppression Trial II (CAST II). Control Clin Trials. 1994 Dec;15(6):437-49.
•   Capone RJ, Pawitan Y, el-Sherif N, Geraci TS, Handshaw K, Morganroth J, Schlant RC, Waldo AL
  Events in the cardiac arrhythmia suppression trial: baseline predictors of mortality in placebo-treated patients. J Am Coll Cardiol. 1991 Nov 15;18(6):1434-8.
•   Denes P, el-Sherif N, Katz R, Capone R, Carlson M, Mitchell LB, Ledingham R
  Prognostic significance of signal-averaged electrocardiogram after thrombolytic therapy and/or angioplasty during acute myocardial infarction (CAST substudy). Cardiac Arrhythmia Suppression Trial (CAST) SAECG Substudy Investigators. Am J Cardiol. 1994 Aug 1;74(3):216-20.
•   Denes P, Gillis AM, Pawitan Y, Kammerling JM, Wilhelmsen L, Salerno DM
  Prevalence, characteristics and significance of ventricular premature complexes and ventricular tachycardia detected by 24-hour continuous electrocardiographic recording in the Cardiac Arrhythmia Suppression Trial. CAST Investigators. Am J Cardiol. 1991 Oct 1;68(9):887-96.
•   Echt DS, Liebson PR, Mitchell LB, Peters RW, Obias-Manno D, Barker AH, Arensberg D, Baker A, Friedman L, Greene HL, et al
  Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The Cardiac Arrhythmia Suppression Trial. N Engl J Med. 1991 Mar 21;324(12):781-8.
•   Effect of the antiarrhythmic agent moricizine on survival after myocardial infarction
  The Cardiac Arrhythmia Suppression Trial II Investigators. N Engl J Med. 1992 Jul 23;327(4):227-33.
•   el-Sherif N, Denes P, Katz R, Capone R, Mitchell LB, Carlson M, Reynolds-Haertle R
  Definition of the best prediction criteria of the time domain signal-averaged electrocardiogram for serious arrhythmic events in the postinfarction period. The Cardiac Arrhythmia Suppression Trial/Signal-Averaged Electrocardiogram (CAST/SAECG) Substudy Investigators. J Am Coll Cardiol. 1995 Mar 15;25(4):908-14.
•   Epstein AE, Bigger JT Jr, Wyse DG, Romhilt DW, Reynolds-Haertle RA, Hallstrom AP
  Events in the Cardiac Arrhythmia Suppression Trial (CAST): mortality in the entire population enrolled. J Am Coll Cardiol. 1991 Jul;18(1):14-9. Erratum in: J Am Coll Cardiol 1991 Sep;18(3):888.
•   Epstein AE, Hallstrom AP, Rogers WJ, Liebson PR, Seals AA, Anderson JL, Cohen JD, Capone RJ, Wyse DG
  Mortality following ventricular arrhythmia suppression by encainide, flecainide, and moricizine after myocardial infarction. The original design concept of the Cardiac Arrhythmia Suppression Trial (CAST). JAMA. 1993 Nov 24;270(20):2451-5.
•   Every NR, Hlatky MA, McDonald KM, Weaver WD, Hallstrom AP
  Estimating the proportion of post-myocardial infarction patients who may benefit from prophylactic implantable defibrillator placement from analysis of the CAST registry. Cardiac Arrhythmia Suppression Trial. Am J Cardiol. 1998 Sep 1;82(5):683-5, A8.
•   Friedman LM, Bristow JD, Hallstrom A, Schron E, Proschan M, Verter J, DeMets D, Fisch C, Nies AS, Ruskin J, et al
  Data monitoring in the cardiac arrhythmia suppression trial. Online J Curr Clin Trials. 1993 Jul 31;Doc No 79:[5870 words; 53 paragraphs].
•   Friedmann E, Thomas SA
  Pet ownership, social support, and one-year survival after acute myocardial infarction in the Cardiac Arrhythmia Suppression Trial (CAST). Am J Cardiol. 1995 Dec 15;76(17):1213-7.
•   Goldstein S, Brooks MM, Ledingham R, Kennedy HL, Epstein AE, Pawitan Y, Bigger JT
  Association between ease of suppression of ventricular arrhythmia and survival. Circulation. 1995 Jan 1;91(1):79-83.
•   Goldstein S, Zoble RG, Akiyama T, Cohen JD, Lancaster S, Liebson PR, Rapaport E, Goldberg AD, Peters RW, Gillis AM
  Relation of circadian ventricular ectopic activity to cardiac mortality. CAST Investigators. Am J Cardiol. 1996 Oct 15;78(8):881-5.
•   Gorkin L, Schron EB, Brooks MM, Wiklund I, Kellen J, Verter J, Schoenberger JA, Pawitan Y, Morris M, Shumaker S
  Psychosocial predictors of mortality in the Cardiac Arrhythmia Suppression Trial-1 (CAST-1). Am J Cardiol. 1993 Feb 1;71(4):263-7.
•   Gorkin L, Schron EB, Handshaw K, Shea S, Kinney MR, Branyon M, Campion J, Bigger JT Jr, Sylvia SC, Duggan J, Stylianou M, Lancaster S, Ahern DK, Follick MJ
  Clinical trial enrollers vs. nonenrollers: the Cardiac Arrhythmia Suppression Trial (CAST) Recruitment and Enrollment Assessment in Clinical Trials (REACT) project. Control Clin Trials. 1996 Feb;17(1):46-59.
•   Greene HL, Roden DM, Katz RJ, Woosley RL, Salerno DM, Henthorn RW
  The Cardiac Arrhythmia Suppression Trial: first CAST ... then CAST-II. J Am Coll Cardiol. 1992 Apr;19(5):894-8.
•   Hallstrom A, Friedman L, Denes P, Rizo-Patron C, Morris M; CAST Investigators; AVID Investigators
  Do arrhythmia patients improve survival by participating in randomized clinical trials? Observations from the Cardiac Arrhythmia Suppression Trial (CAST)and the Antiarrhythmics Versus Implantable Defibrillators Trial (AVID). Control Clin Trials. 2003 Jun;24(3):341-52.
•   Hallstrom A, Pratt CM, Greene HL, Huther M, Gottlieb S, DeMaria A, Young JB
  Relations between heart failure, ejection fraction, arrhythmia suppression and mortality: analysis of the Cardiac Arrhythmia Suppression Trial. J Am Coll Cardiol. 1995 May;25(6):1250-7.
•   Hallstrom AP, Anderson JL, Carlson M, Davies R, Greene HL, Kammerling JM, Romhilt DW, Duff HJ, Huther M
  Time to arrhythmic, ischemic, and heart failure events: exploratory analyses to elucidate mechanisms of adverse drug effects in the Cardiac Arrhythmia Suppression Trial. Am Heart J. 1995 Jul;130(1):71-9.
•   Hallstrom AP, Greene HL, Huther ML
  The healthy responder phenomenon in non-randomized clinical trials. CAST Investigators. Stat Med. 1991 Oct;10(10):1621-31.
•   Hallstrom AP, Verter J, Friedman L
  Randomizing responders. Cardiac Arrhythmia Suppression Trial (CAST) investigators. Control Clin Trials. 1991 Aug;12(4):486-503.
•   Hochman JS, Brooks MM, Morris M, Ahmad T
  Prognostic significance of left ventricular aneurysm in the Cardiac Arrhythmia Suppression Trial (CAST) population. Am Heart J. 1994 Apr;127(4 Pt 1):824-32.
•   Josephson RA, Chahine RA, Morganroth J, Anderson J, Waldo A, Hallstrom A
  Prediction of cardiac death in patients with a very low ejection fraction after myocardial infarction: a Cardiac Arrhythmia Suppression Trial (CAST) study. Am Heart J. 1995 Oct;130(4):685-91.
•   Kellen JC, Ettinger A, Todd L, Brezsnyak ML, Campion J, McBride R, Thomas S, Corum J, Schron E
  The Cardiac Arrhythmia Suppression Trial: Implications for nursing practice. Am J Crit Care. 1996 Jan;5(1):19-25.
•   Kennedy HL, Brooks MM, Barker AH, Bergstrand R, Huther ML, Beanlands DS, Bigger JT, Goldstein S
  Beta-blocker therapy in the Cardiac Arrhythmia Suppression Trial. CAST Investigators. Am J Cardiol. 1994 Oct 1;74(7):674-80.
•   Morganroth J, Bigger JT Jr, Anderson JL
  Treatment of ventricular arrhythmias by United States cardiologists: a survey before the Cardiac Arrhythmia Suppression Trial results were available. Am J Cardiol. 1990 Jan 1;65(1):40-8.
•   Morganroth J, Bigger JT Jr
  Pharmacologic management of ventricular arrhythmias after the cardiac arrhythmia suppression trial. Am J Cardiol. 1990 Jun 15;65(22):1497-503.
•   Obias-Manno D, Friedmann E, Brooks MM, Thomas SA, Haakenson C, Morris M, Wimbush F, Somelofski C, Goldner F
  Adherence and arrhythmic mortality in the cardiac arrhythmia suppression trial (CAST). Ann Epidemiol. 1996 Mar;6(2):93-101.
•   Peters RW, Brooks MM, Todd L, Liebson PR, Wilhelmsen L
  Smoking cessation and arrhythmic death: the CAST experience. The Cardiac Arrhythmia Suppression Trial (CAST) Investigators. J Am Coll Cardiol. 1995 Nov 1;26(5):1287-92.
•   Peters RW, Brooks MM, Zoble RG, Liebson PR, Seals AA
  Chronobiology of acute myocardial infarction: cardiac arrhythmia suppression trial (CAST) experience. Am J Cardiol. 1996 Dec 1;78(11):1198-201.
•   Peters RW, Mitchell LB, Brooks MM, Echt DS, Barker AH, Capone R, Liebson PR, Greene HL
  Circadian pattern of arrhythmic death in patients receiving encainide, flecainide or moricizine in the Cardiac Arrhythmia Suppression Trial (CAST). J Am Coll Cardiol. 1994 Feb;23(2):283-9.
•   Peters RW, Zoble RG, Liebson PR, Pawitan Y, Brooks MM, Proschan M
  Identification of a secondary peak in myocardial infarction onset 11 to 12 hours after awakening: the Cardiac Arrhythmia Suppression Trial (CAST) experience. J Am Coll Cardiol. 1993 Oct;22(4):998-1003.
•   Pratt CM, Brater DC, Harrell FE Jr, Kowey PR, Leier CV, Lowenthal DT, Messerli F, Packer M, Pritchett EL, Ruskin JN
  Clinical and regulatory implications of the Cardiac Arrhythmia Suppression Trial. Am J Cardiol. 1990 Jan 1;65(1):103-5.
•   Pratt CM, Moye L
  The cardiac arrhythmia suppression trial: implications for antiarrhythmic drug development. J Clin Pharmacol. 1990 Nov;30(11):967-74.
•   Pratt CM, Moyé LA
  The cardiac arrhythmia suppression trial. Casting suppression in a different light. Circulation. 1995 Jan 1;91(1):245-7.
•   Pratt CM, Moye LA
  The Cardiac Arrhythmia Suppression Trial: background, interim results and implications. Am J Cardiol. 1990 Jan 16;65(4):20B-29B. Review.
•   Pratt CM
  The Cardiac Arrhythmia Suppression Trial. Introduction: The aftermath of the CAST--a reconsideration of traditional concepts. Am J Cardiol. 1990 Jan 16;65(4):1B-2B.
•   Preliminary report: effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction
  The Cardiac Arrhythmia Suppression Trial (CAST) Investigators. N Engl J Med. 1989 Aug 10;321(6):406-12.
•   Reynolds-Haertle RA, McBride R
  Single vs. double data entry in CAST. Control Clin Trials. 1992 Dec;13(6):487-94.
•   Roose SP, Glassman AH
  Antidepressant choice in the patient with cardiac disease: lessons from the Cardiac Arrhythmia Suppression Trial (CAST) studies. J Clin Psychiatry. 1994 Sep;55 Suppl A:83-7; discussion 88-9, 98-100. Review.
•   Ruskin JN
  The cardiac arrhythmia suppression trial (CAST). N Engl J Med. 1989 Aug 10;321(6):386-8.
•   Schron EB, Brooks MM, Gorkin L, Kellen JC, Morris M, Campion J, Shumaker SA, Corum J
  Relation of sociodemographic, clinical, and quality-of-life variables to adherence in the cardiac arrhythmia suppression trial. Cardiovasc Nurs. 1996 Mar-Apr;32(2):1-6.
•   Shea S, Bigger JT Jr, Campion J, Fleiss JL, Rolnitzky LM, Schron E, Gorkin L, Handshaw K, Kinney MR, Branyon M
  Enrollment in clinical trials: institutional factors affecting enrollment in the cardiac arrhythmia suppression trial (CAST). Control Clin Trials. 1992 Dec;13(6):466-86.
•   Shumaker SA, Brooks MM, Schron EB, Hale C, Kellen JC, Inkster M, Wimbush FB, Wiklund I, Morris M
  Gender differences in health-related quality of life among postmyocardial infarction patients: brief report. CAST Investigators. Cardiac Arrhythmia Suppression Trials. Womens Health. 1997 Spring;3(1):53-60.
•   Thomas SA, Friedmann E, Wimbush F, Schron E
  Psychological factors and survival in the cardiac arrhythmia suppression trial (CAST): a reexamination. Am J Crit Care. 1997 Mar;6(2):116-26.
•   Willund I, Gorkin L, Pawitan Y, Schron E, Schoenberger J, Jared LL, Shumaker S
  Methods for assessing quality of life in the cardiac arrhythmia suppression trial (CAST). Qual Life Res. 1992 Jun;1(3):187-201.
•   Wyse DG, Hallstrom A, McBride R, Cohen JD, Steinberg JS, Mahmarian J
  Events in the Cardiac Arrhythmia Suppression Trial (CAST): mortality in patients surviving open label titration but not randomized to double-blind therapy. J Am Coll Cardiol. 1991 Jul;18(1):20-8.
•   Wyse DG, Morganroth J, Ledingham R, Denes P, Hallstrom A, Mitchell LB, Epstein AE, Woosley RL, Capone R
  New insights into the definition and meaning of proarrhythmia during initiation of antiarrhythmic drug therapy from the Cardiac Arrhythmia Suppression Trial and its pilot study. The CAST and CAPS Investigators. J Am Coll Cardiol. 1994 Apr;23(5):1130-40.

Details for clinical trial NCT00000526